ALNY stock forecast, quote, news & analysis
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics... Show more
Alnylam Pharmaceuticals (ALNY) Stock Analysis: Amvuttra Guidance Reset Weighs on RNAi Leader
Key Takeaways
- Alnylam Pharmaceuticals (ALNY) traded near $231 in mid-October 2026, a decline of roughly 3.7% over the trailing 30 days.
- The stock has been pressured by a lowered 2026 TTR (transthyretin) revenue outlook announced alongside second-quarter results, centered on Amvuttra.
- Analyst sentiment is mixed: UBS initiated coverage with a Buy and a $354 target, while Citi and Wells Fargo trimmed their price targets.
- Third-quarter 2026 results, scheduled for October 29, 2026, represent the next major catalyst for the shares.
- Amvuttra and the broader ATTR amyloidosis franchise remain the core growth engine, with pipeline readouts and the 340B legal decision as key swing factors.
Current Market Snapshot
Alnylam Pharmaceuticals shares have traded in a relatively narrow, downward-tilting range in recent weeks. After closing near $239 in mid-September, the stock slipped to roughly $231 by mid-October, a modest decline that leaves the shares below their 20-day moving average and near the lower end of the one-month range. The move reflects a broader reset in investor expectations following a reduction in full-year 2026 TTR guidance, rather than a sharp, single-event shock. Within the biotechnology sector, sentiment toward Alnylam remains constructive on the long-term RNA interference (RNAi) platform but cautious on near-term commercial execution and valuation.
Alnylam Pharmaceuticals (ALNY) Business Overview and Competitive Position
Alnylam Pharmaceuticals is the pioneer and leading developer of RNA interference therapeutics, a Nobel Prize-winning approach that silences disease-causing genes to prevent the production of pathogenic proteins. The Cambridge, Massachusetts-based company has translated the science into six approved medicines and a commercial footprint spanning more than 70 countries. Its flagship product, Amvuttra (vutrisiran), is the first and only silencer approved for both the cardiomyopathy and polyneuropathy forms of transthyretin (ATTR) amyloidosis, while Onpattro (patisiran), Givlaari (givosiran), and Oxlumo (lumasiran) address additional rare diseases.
The company's competitive strength lies in its durable RNAi platform, its leadership position in the rapidly expanding ATTR market, and a deep clinical pipeline that includes next-generation TTR silencer nucresiran and zilebesiran for hypertension. Investors follow the stock closely because Amvuttra's ATTR cardiomyopathy launch is one of the sector's most closely watched commercial ramps, and because pipeline data readouts can meaningfully shift the company's long-term growth trajectory.
Recent Developments Driving ALNY
The most consequential recent development was the July 30, 2026 revision to full-year 2026 TTR net product revenue guidance. Management narrowed the range to $4.20 billion to $4.50 billion, down from a prior $4.40 billion to $4.70 billion, citing a moderation in second-line Amvuttra demand growth as the ATTR cardiomyopathy launch normalized following its early expansion phase. The reset reframed near-term expectations and triggered a wave of analyst revisions, with some firms lowering price targets while maintaining overall constructive ratings.
In mid-October, UBS initiated coverage with a Buy rating and a $354 price target, citing confidence in Amvuttra and the prospect of a successful Phase 3 readout for nucresiran. Citi lowered its target to $320 from $340 while keeping a Buy, and Wells Fargo trimmed its target to $253 from $256 with an Equal Weight rating, noting that Q3 U.S. Amvuttra data may benefit from an extra selling week but flagging the fourth quarter as the true test of the company's reset guidance. Analysts have also pointed to the timing of an anticipated 340B-related legal ruling as a potential near-term swing factor.
On the clinical front, Alnylam presented data at the European Society of Cardiology (ESC) Congress 2026, including additional HELIOS-B analyses for vutrisiran and Phase 2 KARDIA-3 subgroup data for zilebesiran in uncontrolled hypertension. These presentations reinforced the scientific foundation of the pipeline even as the commercial guidance reset weighed on sentiment.
Trending AI Robots
For traders seeking a data-driven edge across the market, Tickeron's Trending AI Robots page curates a focused selection of the platform's most relevant and top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the highest-performing and most pertinent bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches that align with different risk profiles and trading styles. Reviewing the curated list can help investors identify patterns and strategies that are currently gaining traction in the market.
2026 Outlook and What Investors Should Watch
Heading into the remainder of 2026, the central question for Alnylam is whether Amvuttra's ATTR cardiomyopathy launch can sustain meaningful growth within the company's revised guidance framework. The third-quarter earnings report on October 29, 2026 will provide the first clear read on that trajectory, with particular attention to second-line demand trends, U.S. prescription data, and any update to full-year expectations. The fourth quarter, which several analysts describe as the real test of the reset guidance, will be equally important.
Beyond commercial execution, investors should monitor the Phase 3 readout for nucresiran, the next-generation TTR silencer that could extend Alnylam's franchise leadership, as well as continued data from the zilebesiran program in hypertension. Macroeconomic factors, including interest-rate sensitivity across the biotech sector, and regulatory developments such as the pending 340B ruling, could also influence the shares. As with any clinical-stage growth story, pipeline setbacks or slower-than-expected adoption in the ATTR cardiomyopathy market remain key risks to the outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALNY in downward trend: 10-day moving average moved below 50-day moving average on October 08, 2026
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 54 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 34 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ALNY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 219 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.613) is normal, around the industry mean (3.104). P/E Ratio (26.917) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology